Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.42 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12957993 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL24208105 | 0.90 | ALDH1A1 (0.48) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL2860747 | 0.89 | ALDH1A1 (0.50) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL2860756 | 0.89 | ALDH1A1 (0.50) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL24614964 | 0.89 | ALDH1A1 (0.57) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL23991794 | 0.87 | ALDH1A1 (0.58) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL11961097 | 0.87 | ALDH1A1 (0.58) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL24108714 | 0.87 | ALDH1A1 (0.58) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL11913763 | 0.87 | ALDH1A1 (0.58) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL3488149 | 0.87 | ALDH1A1 (0.58) | ALDH1A1CNR1CNR2LPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016929-B2 | Lipid formulations for delivery of therapeutic agents | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-06-25 | — | — | US | disclosed |
| US-11786598-B2 | Lipid formulations for delivery of therapeutic agents | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-10-17 | — | — | US | disclosed |
| US-11786598-B2 | Lipid formulations for delivery of therapeutic agents | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-10-17 | — | — | US | disclosed |
| US-20230248831-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-08-10 | — | — | US | disclosed |
| US-20230248831-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-08-10 | — | — | US | disclosed |
| US-20190240339-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2019-08-08 | — | — | US | disclosed |
| US-20180071397-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-03-15 | — | — | US | disclosed |
| US-20180071397-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-03-15 | — | — | US | disclosed |
| US-9878042-B2 | Lipid formulations for delivery of therapeutic agents to solid tumors | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2018-01-30 | — | — | US | disclosed |
| US-9878042-B2 | Lipid formulations for delivery of therapeutic agents to solid tumors | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2018-01-30 | — | — | US | disclosed |
| US-8236943-B2 | Compositions and methods for silencing apolipoprotein B | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2012-08-07 | — | — | US | disclosed |
| US-8236943-B2 | Compositions and methods for silencing apolipoprotein B | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2012-08-07 | — | — | US | disclosed |
| US-20110201667-A1 | COMPOSITIONS AND METHODS FOR SILENCING EBOLA VIRUS GENE EXPRESSION | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-08-18 | — | — | US | disclosed |
| US-20110201667-A1 | COMPOSITIONS AND METHODS FOR SILENCING EBOLA VIRUS GENE EXPRESSION | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-08-18 | — | — | US | disclosed |
| WO-2011038160-A2 | COMPOSITIONS AND METHODS FOR SILENCING GENES EXPRESSED IN CANCER | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-03-31 | — | — | WO | disclosed |
| US-20110076335-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-03-31 | — | — | US | disclosed |
| US-20110076335-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-03-31 | — | — | US | disclosed |
| WO-2011011447-A1 | COMPOSITIONS AND METHODS FOR SILENCING EBOLA VIRUS GENE EXPRESSION | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-01-27 | — | — | WO | disclosed |
| WO-2011000106-A1 | IMPROVED CATIONIC LIPIDS AND METHODS FOR THE DELIVERY OF THERAPEUTIC AGENTS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011000108-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110076335-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | PNLIP, CETP, NPC1L1 | ALDH1A1 2057/4885CNR1 3865/4885CNR2 4215/4885 |
| US-20230248831-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | PNLIP, NPC1L1, CETP | ALDH1A1 2161/4885CNR1 3653/4885CNR2 3995/4885 |
| US-20190240339-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | PNLIP, CETP, NPC1L1 | ALDH1A1 2057/4885CNR1 3865/4885CNR2 4215/4885 |
| US-20110201667-A1 | COMPOSITIONS AND METHODS FOR SILENCING EBOLA VIRUS GENE EXPRESSION | BST2, AGO2, SCARB1 | ALDH1A1 3813/4885CNR1 3977/4885CNR2 4387/4885 |
| US-11786598-B2 | Lipid formulations for delivery of therapeutic agents | CETP, PNLIP, NPC1L1 | ALDH1A1 1878/4885CNR1 3702/4885CNR2 4058/4885 |
| US-20180071397-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | PNLIP, CETP, NPC1L1 | ALDH1A1 2057/4885CNR1 3865/4885CNR2 4215/4885 |
| US-12016929-B2 | Lipid formulations for delivery of therapeutic agents | CETP, PNLIP, NPC1L1 | ALDH1A1 1878/4885CNR1 3702/4885CNR2 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.